Expression of cancer stem cell markers is prognostic in metastatic gastroesophageal adenocarcinoma
Daniel Brungs(University of Wollongong), Marie Ranson(University of Wollongong), Sarennya Pathmanandavel(St Vincent's Hospital Sydney), Morteza Aghmesheh(New South Wales Department of Health), Nicholas Hirst(Royal Prince Alfred Hospital), Kara L. Vine(University of Wollongong), Therese M. Becker(Liverpool Hospital), Martin Illemann(University of Copenhagen), Winston Liauw(St George Hospital), Alistair Lochhead(University of Wollongong), Ashleigh Splitt(Wollongong Hospital), Peter Colligan(Wollongong Hospital), Anita Iyer(Wollongong Hospital), Martin Carolan(University of Wollongong)
Cited by 14
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities
|Journal of Controlled Release|2018|297
Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
|British Journal of Clinical Pharmacology|2004|272
Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
|Anti-Cancer Agents in Medicinal Chemistry|2009|269